Stock listing
Munich:S49 Supernus Pharmaceuticals, Inc. Aktie
German listing (Munich) of Supernus Pharmaceuticals, Inc. · home listing NASDAQ:SUPN
Follow Supernus Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SUPN
$28.61 USD -0.35 (-1.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SUPN
- Day range
- $28.15 – $29.51 USDNov 20, 2026
- Volume
- 2.83M sharesNov 20, 2026
- Market cap
- $1.67B USDAt the close on Nov 20, 2026 · price × 58.22M shares outstanding
- 52-week range
- $25.92 – $42.81 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $89.36M USDMedian day 2.22M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SUPN · Home | $28.61 USD | -0.35 (-1.2%) | 2,831,327 | $28.39 | $29.51 | $28.15 | $28.96 | Close on Nov 20, 2026 |
| LSE:0LB2 | $30.33 USD | -12.44 (-29.1%) | 42 | $30.33 | $30.33 | $30.33 | $42.77 | Close on Nov 3, 2026 |
| Frankfurt:S49 | €24.48 EUR | +1.251 (+5.4%) | 2 | €24.48 | €24.48 | €24.48 | €23.23 | Close on Nov 5, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SUPN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $28.61 | -0.35 | -1.2% | $28.39 | $29.51 | $28.15 | 2,831,327 | |
| $28.96 | -0.08 | -0.3% | $29.21 | $29.75 | $28.69 | 2,714,267 | |
| $29.04 | +0.21 | +0.7% | $28.72 | $29.69 | $28.46 | 2,810,120 | |
| $28.83 | -0.89 | -3.0% | $29.43 | $29.61 | $28.40 | 3,782,231 | |
| $29.72 | +0.52 | +1.8% | $29.41 | $29.92 | $28.82 | 2,071,488 | |
| $29.20 | -0.25 | -0.8% | $29.48 | $30.17 | $28.79 | 4,365,750 | |
| $29.45 | +0.70 | +2.4% | $28.75 | $29.66 | $28.71 | 3,072,550 | |
| $28.75 | +1.13 | +4.1% | $27.61 | $28.83 | $27.33 | 2,784,892 | |
| $27.62 | +1.46 | +5.6% | $26.54 | $27.91 | $26.11 | 2,574,732 | |
| $26.16 | -0.58 | -2.2% | $26.58 | $27.08 | $25.92 | 4,363,419 | |
| $26.74 | -1.47 | -5.2% | $28.29 | $28.79 | $26.52 | 6,080,379 | |
| $28.21 | +0.06 | +0.2% | $26.81 | $28.99 | $26.74 | 6,565,162 | |
| $28.15 | -8.13 | -22.4% | $28.35 | $31.62 | $27.97 | 9,053,152 | |
| $36.28 | +0.91 | +2.6% | $35.43 | $37.02 | $35.32 | 4,869,435 | |
| $35.37 | +0.12 | +0.3% | $34.78 | $36.49 | $34.62 | 4,607,200 | |
| $35.25 | +0.48 | +1.4% | $36.53 | $37.00 | $34.53 | 5,718,700 | |
| $34.77 | +0.05 | +0.1% | $34.39 | $34.86 | $33.84 | 1,529,600 | |
| $34.72 | +0.16 | +0.5% | $34.68 | $34.82 | $33.93 | 2,410,600 | |
| $34.56 | +0.09 | +0.3% | $34.47 | $34.65 | $33.99 | 916,600 | |
| $34.47 | -0.86 | -2.4% | $35.35 | $35.35 | $34.10 | 1,484,000 | |
| $35.33 | +0.54 | +1.6% | $34.77 | $35.36 | $34.54 | 871,700 | |
| $34.79 | +0.02 | +0.1% | $34.92 | $35.15 | $34.56 | 3,344,500 | |
| $34.77 | +0.90 | +2.7% | $34.02 | $35.12 | $33.80 | 1,925,300 | |
| $33.87 | +1.42 | +4.4% | $32.60 | $34.19 | $32.48 | 2,276,300 | |
| $32.45 | -1.17 | -3.5% | $33.47 | $33.84 | $32.31 | 4,291,100 | |
| $33.62 | -0.54 | -1.6% | $34.57 | $34.86 | $33.54 | 1,751,000 | |
| $34.16 | -1.26 | -3.6% | $35.11 | $36.30 | $33.99 | 2,781,200 | |
| $35.42 | -0.64 | -1.8% | $36.09 | $36.26 | $35.19 | 1,930,400 | |
| $36.06 | +0.23 | +0.6% | $36.00 | $36.32 | $35.37 | 7,474,000 | |
| $35.83 | +0.38 | +1.1% | $35.45 | $36.14 | $35.21 | 4,799,600 | |
| $35.45 | -0.68 | -1.9% | $35.73 | $36.35 | $34.85 | 1,527,200 | |
| $36.13 | +0.23 | +0.6% | $35.58 | $36.30 | $35.58 | 1,769,600 | |
| $35.90 | -0.09 | -0.3% | $35.96 | $36.15 | $35.03 | 2,390,500 | |
| $35.99 | +0.28 | +0.8% | $36.00 | $36.26 | $35.73 | 3,003,300 | |
| $35.71 | +0.33 | +0.9% | $35.46 | $36.15 | $35.26 | 1,669,300 | |
| $35.38 | -0.47 | -1.3% | $35.85 | $36.21 | $35.25 | 1,879,000 | |
| $35.85 | -0.74 | -2.0% | $36.54 | $36.60 | $35.79 | 1,673,600 | |
| $36.59 | -0.29 | -0.8% | $36.74 | $37.05 | $36.08 | 2,005,500 | |
| $36.88 | +1.06 | +3.0% | $35.50 | $36.96 | $35.43 | 1,173,500 | |
| $35.82 | -0.18 | -0.5% | $35.90 | $36.22 | $35.72 | 1,098,400 | |
| $36.00 | +0.09 | +0.3% | $35.71 | $36.28 | $35.57 | 2,221,700 | |
| $35.91 | -0.28 | -0.8% | $36.23 | $36.90 | $35.78 | 1,058,000 | |
| $36.19 | +0.66 | +1.9% | $35.53 | $36.63 | $35.48 | 2,216,100 | |
| $35.53 | +0.65 | +1.9% | $35.00 | $35.63 | $34.77 | 1,299,000 | |
| $34.88 | -0.81 | -2.3% | $35.59 | $35.62 | $34.59 | 4,684,200 | |
| $35.69 | +1.34 | +3.9% | $34.76 | $35.90 | $34.47 | 2,690,500 | |
| $34.35 | +0.13 | +0.4% | $33.97 | $34.54 | $33.84 | 1,865,900 | |
| $34.22 | -0.25 | -0.7% | $34.59 | $34.59 | $33.74 | 2,700,600 | |
| $34.47 | -0.02 | -0.1% | $34.74 | $35.01 | $34.15 | 3,429,300 | |
| $34.49 | -0.02 | -0.1% | $34.49 | $34.83 | $34.23 | 1,297,200 | |
| $34.51 | -0.26 | -0.7% | $34.58 | $34.87 | $34.04 | 1,319,500 | |
| $34.77 | +0.45 | +1.3% | $34.32 | $34.80 | $33.92 | 1,351,700 | |
| $34.32 | -0.62 | -1.8% | $34.35 | $34.84 | $33.84 | 1,823,800 | |
| $34.94 | +0.11 | +0.3% | $34.74 | $35.31 | $34.55 | 1,019,400 | |
| $34.83 | -0.22 | -0.6% | $35.18 | $35.23 | $34.57 | 1,825,600 | |
| $35.05 | +0.49 | +1.4% | $34.74 | $35.28 | $34.68 | 2,975,000 | |
| $34.56 | -0.37 | -1.1% | $35.00 | $35.44 | $34.50 | 2,094,800 | |
| $34.93 | +0.06 | +0.2% | $34.87 | $35.30 | $34.33 | 1,963,300 | |
| $34.87 | -0.43 | -1.2% | $35.31 | $35.49 | $34.49 | 3,308,700 | |
| $35.30 | -0.525 | -1.5% | $35.61 | $35.95 | $35.11 | 1,220,400 | |
| $35.83 | -0.145 | -0.4% | $35.90 | $36.21 | $35.55 | 1,275,300 | |
| $35.97 | -0.21 | -0.6% | $36.23 | $36.75 | $35.61 | 1,712,100 | |
| $36.18 | -0.69 | -1.9% | $36.53 | $36.82 | $35.37 | 1,840,800 | |
| $36.87 | -0.91 | -2.4% | $37.68 | $38.52 | $36.70 | 2,496,700 | |
| $37.78 | -1.26 | -3.2% | $38.91 | $39.25 | $37.64 | 1,442,300 |
Splits
1 split · NASDAQ:SUPN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- Munich:S49
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Munich
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
Latest earnings call · Oct 29, 2026
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q3 2026 Earnings Presentation
Earnings · 7 slides
Latest news
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
Nov 10, 2026
Closed $28.75 (+4.1%) on Nov 10, 2026
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Nov 2, 2026
Closed $36.28 (+2.6%) on Nov 2, 2026
Supernus Announces Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $35.37 (+0.3%) on Oct 30, 2026
Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
Oct 28, 2026
Closed $34.77 (+0.1%) on Oct 28, 2026
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Oct 21, 2026
Closed $35.33 (+1.6%) on Oct 22, 2026
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Oct 19, 2026
Closed $33.87 (+4.4%) on Oct 19, 2026
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Aug 31, 2026
Closed $34.93 (+0.2%) on Aug 31, 2026
Supernus Announces Second Quarter 2026 Financial Results
Aug 3, 2026
Closed $37.37 (-6.6%) on Aug 3, 2026
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Aug 3, 2026
Closed $37.37 (-6.6%) on Aug 3, 2026
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Jul 22, 2026
Closed $40.51 (+0.1%) on Jul 23, 2026
Supernus Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 20 in the last 12 months · 162 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Oct 29, 2026
- Decks
- 18 decks · latest Oct 29, 2026
Where Supernus Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SUPN · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A1JX3U | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1JX3U | LS Exchange | Germany | EUR |
| gettex:S49 | gettex | Germany | EUR |
| BOATS:SUPN | BOATS | United States | USD |
| LSE:0LB2 | LSE | United Kingdom | USD |
| Frankfurt:S49 | Frankfurt | Germany | EUR |
| BX Swiss:S49 | BX Swiss | Switzerland | CHF |
| Dusseldorf:S49 | Dusseldorf | Germany | EUR |
| Munich:S49 · This page | Munich | Germany | EUR |
| Stuttgart:S49 | Stuttgart | Germany | EUR |
| Tradegate:S49 | Tradegate | Germany | EUR |
Valuation
P/E 3.7× against a median of 18.5×: the lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.85B USD
- P/E
- 3.7×
- EV/sales
- 1.4×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 85.1%
- Operating margin
- 40.6%
- Net margin
- 32.9%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.67
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN | US$1.67B | US$1.85B | 3.7× | 1.4× | n/a | n/a | 32.9% | n/a | 0.67 |
| Harbin Pharmaceutical Group Co., Ltd. Class A · SSE:600664 | US$1.70B | US$1.22B | 17.9× | 0.5× | n/a | 1.8× | 3.9% | 0.0× | n/a |
| Mayinglong Pharmaceutical Group Co., Ltd. Class A · SSE:600993 | US$1.70B | US$1.34B | 19.1× | 2.2× | n/a | 2.5× | 14.9% | 0.0× | n/a |
| Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE | US$1.68B | US$2.60B | n/a | 3.6× | n/a | n/a | −71.8% | n/a | 1.35 |
| Caplin Point Laboratories Limited · NSE:CAPLIPOINT | US$1.66B | US$1.56B | 23.2× | 6.3× | 18.1× | 4.3× | 29.1% | 0.0× | n/a |
| AstraZeneca Pharma India Limited · NSE:ASTRAZEN | US$1.66B | US$1.60B | 86.8× | 5.7× | 59.3× | 17.5× | 6.8% | 0.0× | n/a |
| Hugel, Inc. · KRX:145020 | US$1.66B | US$1.21B | 14.1× | 3.4× | 7.1× | 2.1× | 32.9% | 0.0× | n/a |
| Agios Pharmaceuticals, Inc. · NASDAQ:AGIO | US$1.65B | US$1.05B | n/a | 7.4× | n/a | 1.7× | −264.8% | 0.0× | 1.10 |
| Faes Farma, S.A. · BME:FAE | US$1.65B | US$1.93B | 11.0× | 1.7× | 5.8× | 1.9× | 13.1% | 0.5× | n/a |
| Consun Pharmaceutical Group Ltd. · HKEX:1681 | US$1.64B | US$1.07B | 10.1× | 2.1× | 5.6× | 2.3× | 31.6% | 0.1× | n/a |
| BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166 | US$1.63B | US$1.68B | 106× | 8.3× | n/a | 3.5× | 7.6% | 0.5× | n/a |
| Median of the others | US$1.66B | US$1.45B | 18.5× | 3.5× | 7.1× | 2.3× | 10.3% | 0.0× | 1.23 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 55.33 USD · Analysts' mean
- EPS, year to Dec 2026
- 3.44 · 1 analyst
- Revenue, year to Dec 2026
- 1.68B · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jack A. Khattar | President and Chief Executive Officer, Director |
| Timothy C. Dec | Senior Vice President, Chief Financial Officer |
| Bryan A. Roecklein | Senior Vice President, Chief Business Officer |
| Frank Mottola | Senior Vice President, Chief Technical Operations Officer |
| Jeff Bozick | Senior Vice President, Supply Chain |
| Jonathan Rubin | Senior Vice President, Chief Medical Officer, Research & Development |
| Padmanabh P. Bhatt | Senior Vice President, Chief Scientific Officer, Intellectual Property |
| Roman Bradel | Vice President, Regulatory Affairs |
| Taylor Raiford | Senior Vice President, Sales |
| Todd Horich | Senior Vice President, Chief Commercial Officer |
| Kevin Espinoza | Chief Integrity and Compliance Officer |
Board
| Director | Role |
|---|---|
| Bethany Sensenig | INDEPENDENT NON-EXECUTIVE DIRECTOR |
| Carrolee Barlow | INDEPENDENT NON-EXECUTIVE DIRECTOR |
| Georges Gemayel | INDEPENDENT NON-EXECUTIVE DIRECTOR |
| Jack A. Khattar | President and Chief Executive Officer, Director |
| Juliet Thompson | INDEPENDENT NON-EXECUTIVE DIRECTOR |
| Keith Humphreys | INDEPENDENT NON-EXECUTIVE DIRECTOR |
| Mark Stejbach | INDEPENDENT NON-EXECUTIVE DIRECTOR |
Events
Calls
| Call | When | Status |
|---|---|---|
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2024 Earnings Call | Tue, Feb 25, 2025 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2024 Earnings Call | Mon, Nov 04, 2024 · 4:30 PM ET | Replay |
| Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | +0.3% |
| Q2 2026 | Aug 3, 2026 · Before open | −6.6% |
| Q1 2026 | May 5, 2026 · After close | +2.6% |
| Q4 2025 | Mar 3, 2026 | +0.6% |
| Q3 2025 | Nov 4, 2025 · After close | +0.2% |
| Q2 2025 | Aug 5, 2025 · After close | +0.9% |
| Q1 2025 | May 6, 2025 · After close | −1.9% |
| Q4 2024 | Feb 25, 2025 · Before open | +0.1% |
| Q3 2024 | Nov 4, 2024 · After close | +0.3% |
| Q2 2024 | Aug 6, 2024 · After close | −2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +0.5% |
| Quarter to Dec 31, 2023 | Feb 27, 2024 · After close | −1.6% |
| Quarter to Sep 30, 2023 | Nov 8, 2023 · After close | −5.5% |
| Quarter to Jun 30, 2023 | Aug 8, 2023 · After close | +1.1% |
| Quarter to Mar 31, 2023 | May 9, 2023 · After close | 0.0% |
| Quarter to Dec 31, 2022 | Feb 28, 2023 · After close | −3.7% |
| Quarter to Sep 30, 2022 | Nov 8, 2022 · After close | 0.0% |
| Quarter to Jun 30, 2022 | Aug 4, 2022 · After close | 0.0% |
| Quarter to Mar 31, 2022 | May 9, 2022 · After close | −2.4% |
| Quarter to Dec 31, 2021 | Feb 28, 2022 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 7 slides | Oct 29, 2026 |
| Merger or Acquisition (August 2026) | Merger or acquisition | 11 slides | Aug 3, 2026 |
| Merger or Acquisition (August 2026) | Merger or acquisition | 13 slides | Aug 3, 2026 |
| Investor Presentation (May 2026) | Investor deck | 35 slides | May 2026 |
| Merger or Acquisition (June 2025) | Merger or acquisition | 16 slides | Jun 16, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 32 slides | May 6, 2025 |
| Investor Day (October 2023) | Investor day | 104 slides | Oct 18, 2023 |
| Jefferies Healthcare Conference 2022 | Conference | 23 slides | Jun 9, 2022 |
| Merger or Acquisition (October 2021) | Merger or acquisition | 19 slides | Oct 12, 2021 |
| Technical Presentation (December 2020) | Technical | 8 slides | Dec 23, 2020 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (May 2020) | Merger or acquisition | 26 slides | May 4, 2020 |
| Corporate Update (March 2019) | Corporate update | 14 slides | Mar 28, 2019 |
| Corporate Update (December 2018) | Corporate update | 32 slides | Dec 10, 2018 |
| Debt Investor Presentation (March 2018) | Debt investors | 35 slides | Mar 14, 2018 |
| Corporate Update (October 2016) | Corporate update | 12 slides | Oct 11, 2016 |
| Investor Presentation (March 2015) | Investor deck | 20 slides | March 2015 |
| Investor Presentation (April 2013) | Investor deck | 32 slides | Apr 26, 2013 |
| Stifel and Rodman & Renshaw Conferences 2012 | Conference | 19 slides | September 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.0M |
| Cost of revenue | 246.0M | 231.0M | 174.0M | 151.0M |
| Gross profit | 994.0M | 957.0M | 919.0M | 749.0M |
| Research and development | 97.0M | 107.0M | 116.0M | 74.0M |
| Selling, general and administrative | 634.0M | 612.0M | 565.0M | 466.0M |
| Operating income | 262.0M | 38.0M | -152.0M | -77.0M |
| Depreciation and amortization | 10.0M | 16.0M | 15.0M | 16.0M |
| EBITDA | 272.0M | 54.0M | -137.0M | -61.0M |
| Interest expense | 45.0M | 41.0M | 35.0M | 27.0M |
| Income before tax | 239.0M | 20.0M | -145.0M | -86.0M |
| Income tax | 29.0M | 13.0M | -19.0M | -43.0M |
| Net income | 210.0M | 7.00M | -126.0M | -42.0M |
| Earnings per share, basic | 1.68 | 0.05 | -0.92 | -0.30 |
| Earnings per share, diluted | 1.64 | 0.05 | -0.92 | -0.30 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 195.0M | 319.0M | 316.0M | 774.0M |
| Short-term investments | 0 | 1.00M | 94.0M | |
| Receivables | 253.0M | 254.0M | 254.0M | |
| Inventory | 153.0M | 167.0M | 126.0M | |
| Current assets | 652.0M | 827.0M | 1.26B | |
| Property, plant and equipment | 144.0M | 100.0M | 84.0M | |
| Goodwill | 2.00M | 2.00M | 5.00M | |
| Total assets | 1.20B | 1.32B | 1.76B | |
| Accounts payable | 48.0M | 63.0M | 39.0M | |
| Current liabilities | 914.0M | 924.0M | 1.28B | |
| Long-term debt | 290.0M | 315.0M | 237.0M | |
| Total debt | 319.0M | 333.0M | 240.0M | |
| Total liabilities | 1.30B | 1.65B | 1.94B | |
| Shareholders' equity | -98.0M | -337.0M | -184.0M | -15.0M |
| Shares outstanding | 118.0M | 118.0M | 125.1M | 125.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -27.0M | 36.0M | -300.0M | -4.00M |
| Capital spending | -66.0M | -29.0M | -8.00M | -5.00M |
| Free cash flow | -93.0M | 7.00M | -308.0M | -9.00M |
| Cash from investing | -66.0M | 69.0M | -95.0M | -222.0M |
| Cash from financing | -30.0M | -102.0M | -64.0M | -101.0M |
| Share buybacks | -11.0M | -173.0M | -33.0M | -90.0M |
| Change in cash | -124.0M | 3.00M | -459.0M | -327.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 8-K · Current report | Nov 2, 2026 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 425 | Oct 29, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 8-K · Current report | Oct 15, 2026 | Meeting outcome | SEC |
| 425 | Oct 6, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 30, 2026 | Big-stake notice | SEC |
| 425 | Sep 17, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 17, 2026 | Current report | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 14, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 11, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Sep 9, 2026 | Offer document | SEC |
| S-4 · Registration statement | Aug 28, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 425 | Aug 3, 2026 | Other filings | SEC |
| 425 | Aug 3, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 3, 2026 | Quarterly report | SEC |
| 425 | Aug 3, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 425 | Aug 3, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| 425 | Aug 3, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 3, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Jun 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 8-K · Current report | May 15, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 17, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 15-12G | Jan 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 26, 2026 | Offer document | SEC |
| S-8 POS | Jan 26, 2026 | Offer document | SEC |
| S-8 POS | Jan 26, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 26, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 22, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 22, 2025 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 15, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 20, 2025 | Current report | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Oct 30, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 5, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 28, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Aug 4, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 8-K · Current report | Jun 24, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | May 9, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 8, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 23, 2025 | Results | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Mar 20, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 3, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 27, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 25, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 24, 2025 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Feb 20, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 12, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 6, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Feb 4, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 4, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 4, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 3, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 3, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 28, 2025 | Current report | SEC |
This page holds 200 of 572 filings. Open Filings
Cap table
Built by 6ix from Supernus Pharmaceuticals, Inc.’s releases
- Common shares
- 58,224,143
- Fully diluted
- 58,224,143
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 58,224,143 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 58,224,143 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Samuel D Isaly Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Aug 31, 2017 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 13, 2007 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past) | Director · May 4, 2012 – May 4, 2012 · Past |
| Daniel Ninivaggi Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least Mar 4, 2025); Garrett Motion Inc. (CHAIRMAN OF THE BOARD · Since at least Apr 30, 2021); Nu Ride Inc (FORMER EXECUTIVE CHAIRMAN, Director · Mar 14, 2024 – Mar 14, 2024 · Past); Navistar International Corporation (Director · Aug 14, 2017 – Sep 30, 2018 · Past); Hertz Global Holdings, Inc (Director · Jun 30, 2016 – Jun 30, 2021 · Past); Herc Holdings Inc. (Director · Sep 15, 2014 – May 18, 2016 · Past); American Railcar Industries Inc (Director · Jun 4, 2013 – Feb 6, 2014 · Past); CVR Refining LP (Director · Jan 16, 2013 – Jan 16, 2013 · Past); CVR Partners, LP (Director · May 10, 2012 – May 10, 2012 · Past); CVR Energy Inc. (Director · May 7, 2012 – May 7, 2012 · Past); Motorola Mobility Holdings Inc (Director · Dec 1, 2010 – May 22, 2012 · Past); XO Group Inc (Director · Aug 10, 2010 – Aug 10, 2010 · Past); Icahn Enterprises L.P. (President, Director · Apr 5, 2010 – Mar 1, 2013 · Past); Federal-Mogul Corp (Director · Mar 18, 2010 – Mar 18, 2010 · Past); CIT Group Inc (Director · Dec 18, 2009 – May 11, 2010 · Past); Lear Corporation (Executive Vice President · Mar 15, 2006 – Mar 14, 2009 · Past) | Director · Since at least Jan 1, 2026 |
| M James Barrett Other companies: Senseonics Holdings, Inc. (Director · Mar 17, 2016 – May 30, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 15, 2018 · Past); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 30, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Jul 28, 2015 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Crescent Biopharma, Inc. (Director · Jan 9, 2014 – May 18, 2018 · Past); Omthera Pharmaceuticals Inc (Director · Jul 18, 2013 – Jul 18, 2013 · Past); Clovis Oncology Inc (Director · Nov 15, 2011 – Oct 11, 2018 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); Pharmion Corp (Director · Jun 8, 2006 – Mar 7, 2008 · Past); Gyre Therapeutics, Inc. (Director · Apr 11, 2006 – Jun 7, 2012 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past); Iomai Corp (Director · Jan 25, 2006 – Aug 4, 2008 · Past) | Director · Apr 30, 2012 – Mar 16, 2016 · Past |
| David E. Wheadon Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Vaxart, Inc. (Director · Since at least Aug 4, 2022); Sotera Health Company (Director · Since at least May 27, 2022); Karuna Therapeutics Inc (Director · Jun 15, 2022 – Mar 18, 2024 · Past); ChemoCentryx Inc. (Director · May 26, 2022 – Oct 20, 2022 · Past) | Director · Since at least Jan 1, 2026 |
| Barbara Ryan Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Azitra Inc (Director · Since at least Jun 15, 2023); MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); INVO Fertility, Inc. (Director · Since at least Sep 14, 2020) | Director · Since at least Jan 1, 2026 |
| Mark Stejbach Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Flexion Therapeutics Inc (Director · Sep 13, 2016 – Nov 19, 2021 · Past); Alkermes plc (SVP/Chief Comm Off, Alks Inc · Feb 29, 2012 – Mar 1, 2018 · Past); Tengion Inc (VP and Chief Commercial Offcr · Apr 9, 2010 – May 11, 2011 · Past) | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jan 1, 2026 |
| Jack A Khattar Other companies: Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); Scpharmaceuticals Inc (Director · Since at least Nov 16, 2017); Tesaro Inc (President, CEO, Director · Mar 29, 2016 – Mar 29, 2016 · Past) | President, CEO, Director · Since at least Apr 30, 2012 |
| Timothy C. Dec Other companies: CapForce Inc. (Chief Financial Officer · May 4, 2015 – May 17, 2021 · Past); TSS, Inc. (Chief Financial Officer · Aug 20, 2007 – Jun 6, 2012 · Past); Broadwing Corp (SVP Ch. Acct. Officer & Treas. · Mar 20, 2006 – Apr 3, 2006 · Past) | Senior Vice President, Chief Financial Officer · Since at least Aug 23, 2021 |
| Georges Gemayel Other companies: Disc Medicine, Inc. (Director · Since at least Apr 29, 2021); Momenta Pharmaceuticals Inc (Director · Jun 19, 2019 – Oct 1, 2020 · Past) | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Feb 21, 2020 |
| James Patrick Kelly Other companies: Novavax, Inc. (EVP, CFO and Treasurer · Since at least Aug 16, 2021); Vanda Pharmaceuticals Inc. (EVP & Chief Financial Officer · Jan 2, 2020 – Mar 2, 2020 · Past) | Executive Vice-President & CFO · Oct 12, 2020 – Feb 19, 2021 · Past |
All 35 people
| Person | Seat |
|---|---|
| Patrick Barry Other companies: Indivior Pharmaceuticals, Inc. (Chief Commercial Officer · May 27, 2025 – Nov 4, 2026 · Past); Endo International PLC (EVP & Pres,Global Comm Ops · Feb 26, 2018 – Mar 29, 2022 · Past) | Chief Commercial Officer · Since at least Jan 1, 2026 |
| Stuart A Kingsley Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Scholar Rock Holding Corporation (President and CEO, Director · May 20, 2020 – Feb 1, 2021 · Past) | Director · Since at least Jan 1, 2026 |
| Christian Heidbreder Other companies: Indivior Pharmaceuticals, Inc. (Chief Scientific Officer · Since at least Jun 11, 2026) | Chief Scientific Officer · Since at least Jan 1, 2026 |
| Frederick M Hudson Other companies: Scpharmaceuticals Inc (Director · Since at least Jun 18, 2019) | Director · Since at least Feb 21, 2020 |
| Jack A. Khattar Other companies: Cognition Therapeutics, Inc. (Until Apr 20, 2026 · Past) | President and Chief Executive Officer, Director · Since at least Feb 23, 2026 |
| Juliet Thompson Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 12, 2026) | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jan 1, 2026 |
| Keith Humphreys Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026) | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026 |
| Ryan Preblick Other companies: Indivior Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jun 8, 2026) | Chief Financial Officer · Since at least Jan 1, 2026 |
| Woodrow D Anderson Other companies: Indivior Pharmaceuticals, Inc. (Chief Accounting Officer · Since at least Aug 5, 2026) | Chief Accounting Officer · Since at least Jan 1, 2026 |
| Bethany Sensenig | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026 |
| Bryan A. Roecklein | Senior Vice President, Chief Business Officer · Since at least Nov 4, 2026 |
| Carrolee Barlow | INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jun 27, 2018 |
| Charles W Newhall III | Director · Since at least Nov 2, 2026 |
| Frank Mottola | SVP, Chief Tech. Ops. Officer · Since at least Feb 21, 2020 |
| Frank Mottola | Senior Vice President, Chief Technical Operations Officer · Since at least Nov 4, 2026 |
| Gregory S Patrick | Sr. VP Chief Financial Officer · Apr 30, 2012 – Nov 9, 2020 · Past |
| Jeff Bozick | Senior Vice President, Supply Chain · Since at least Nov 4, 2026 |
| Jonathan Rubin | Senior Vice President, Chief Medical Officer, Research & Development · Since at least Jan 1, 2021 |
| Kevin Espinoza | Chief Integrity and Compliance Officer · Since at least Nov 4, 2026 |
| Padmanabh P. Bhatt | Senior Vice President, Chief Scientific Officer, Intellectual Property · Since at least Aug 7, 2025 |
| Roman Bradel | Vice President, Regulatory Affairs · Since at least Nov 4, 2026 |
| Stefan K F Schwabe | Executive Vice President & CMO · Jul 9, 2012 – Dec 21, 2020 · Past |
| Taylor Raiford | Senior Vice President, Sales · Since at least Nov 4, 2026 |
| Todd Horich | Senior Vice President, Chief Commercial Officer · Since at least Nov 4, 2026 |
| William Todd Horich | SVP, Commercial Operations · Since at least Mar 1, 2026 |
Log in to ask 6ix AI your own questions about Supernus Pharmaceuticals, Inc.